Lertcanawanichakul, M.; Bhoopong, P.; Madoromae, H.; Sahabuddeen, T.
Clinical Use, Population-Level Impact, and Antimicrobial Resistance Considerations of Probiotics and Microbiome-Based Therapeutics: Review. Pharmacoepidemiology 2026, 5, 3.
https://doi.org/10.3390/pharma5010003
AMA Style
Lertcanawanichakul M, Bhoopong P, Madoromae H, Sahabuddeen T.
Clinical Use, Population-Level Impact, and Antimicrobial Resistance Considerations of Probiotics and Microbiome-Based Therapeutics: Review. Pharmacoepidemiology. 2026; 5(1):3.
https://doi.org/10.3390/pharma5010003
Chicago/Turabian Style
Lertcanawanichakul, Monthon, Phuangthip Bhoopong, Husna Madoromae, and Tuanhawanti Sahabuddeen.
2026. "Clinical Use, Population-Level Impact, and Antimicrobial Resistance Considerations of Probiotics and Microbiome-Based Therapeutics: Review" Pharmacoepidemiology 5, no. 1: 3.
https://doi.org/10.3390/pharma5010003
APA Style
Lertcanawanichakul, M., Bhoopong, P., Madoromae, H., & Sahabuddeen, T.
(2026). Clinical Use, Population-Level Impact, and Antimicrobial Resistance Considerations of Probiotics and Microbiome-Based Therapeutics: Review. Pharmacoepidemiology, 5(1), 3.
https://doi.org/10.3390/pharma5010003